Top

Current Cardiology Reports

Published in:

Open Access 01-08-2018 | Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?

Authors: I. Karalis, J. W. Jukema

Published in: Current Cardiology Reports | Issue 8/2018

Abstract

Purpose of Review

This review aims to summarize and discuss the recent findings in the field of using HDL mimetics for the treatment of patients with coronary artery disease.

Recent Findings

Following the largely disappointing results with the cholesteryl ester transfer protein inhibitors, focus moved to HDL functionality rather than absolute HDL cholesterol values. A number of HDL/apoA-I mimicking molecules were developed, aiming to enhance reverse cholesterol transport that has been associated with an atheroprotective effect. Three HDL mimetics have made the step from bench-testing to clinical trials in humans and are discussed here: apoA-I Milano, CSL-112, and CER-001. Unfortunately, with the exception of CSL-112 where the results of the clinical trial are not yet known, none of the agents was able to demonstrate a clinical benefit.

Summary

HDL mimetics have failed to date to prove a beneficial effect in clinical practice. Reverse cholesterol transport remains a challenging therapeutic pathway to be explored.

Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16(2):434–44.CrossRefPubMed

Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303(6797):276–82.CrossRefPubMedPubMedCentral

Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188–97. https://doi.org/10.1161/CIR.0b013e3182456d46.CrossRefPubMed

Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1(7897):16–9.CrossRefPubMed

Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med. 1976;88(6):941–57.PubMed

Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707–14.CrossRefPubMed

Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–45. https://doi.org/10.1056/NEJM198711123172001. CrossRefPubMed

Rosenson RS. The high-density lipoprotein puzzle: why classic epidemiology, genetic epidemiology, and clinical trials conflict? Arterioscler Thromb Vasc Biol. 2016;36(5):777–82. https://doi.org/10.1161/ATVBAHA.116.307024.CrossRefPubMed

Karalis I, Rensen PCN, Jukema JW. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Circ Cardiovasc Qual Outcomes. 2013;6(3):360–6. https://doi.org/10.1161/CIRCOUTCOMES.111.000014.CrossRefPubMed

10.

Group HPSTRC, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of Anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–27. https://doi.org/10.1056/NEJMoa1706444. CrossRef

11.

Annema W, Tietge UJ. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr Metab (Lond). 2012;9(1):25. https://doi.org/10.1186/1743-7075-9-25.CrossRef

12.

de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30(4):796–801. https://doi.org/10.1161/ATVBAHA.109.199158.CrossRefPubMedPubMedCentral

13.

Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383–93. https://doi.org/10.1056/NEJMoa1409065. CrossRefPubMedPubMedCentral

14.

Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127–35. https://doi.org/10.1056/NEJMoa1001689. CrossRefPubMedPubMedCentral

15.

Moore RE, M-a K, Kitajima K, Secreto A, Millar JS, Pratico D, et al. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol. 2003;23(10):1914–20. https://doi.org/10.1161/01.ATV.0000092328.66882.F5.CrossRefPubMed

16.

Voyiaziakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL, Huang LS. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res. 1998;39(2):313–21.PubMed

17.

Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JHM, Petersen W, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol. 2004;44(7):1429–35. https://doi.org/10.1016/j.jacc.2004.06.070.CrossRefPubMed

18.

•• Stoekenbroek RM, Stroes ES, Hovingh GK. ApoA-I mimetics. Handb Exp Pharmacol. 2015;224:631–48. https://doi.org/10.1007/978-3-319-09665-0_21. This review article nicely summarizes recent studies with HDL mimetic agents. CrossRefPubMed

19.

Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008;49(6):1344–52. https://doi.org/10.1194/jlr.P800003-JLR200.CrossRefPubMedPubMedCentral

20.

Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res. 2011;52(2):361–73. https://doi.org/10.1194/jlr.M011098.CrossRefPubMedPubMedCentral

21.

Chattopadhyay A, Navab M, Hough G, Gao F, Meriwether D, Grijalva V, et al. A novel approach to oral apoA-I mimetic therapy. J Lipid Res. 2013;54(4):995–1010. https://doi.org/10.1194/jlr.M033555.CrossRefPubMedPubMedCentral

22.

Amar MJA, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, et al. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther. 2010;334(2):634–41. https://doi.org/10.1124/jpet.110.167890.CrossRefPubMedPubMedCentral

23.

Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, et al. The 5A apolipoprotein a-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol. 2010;30(2):246–52. https://doi.org/10.1161/ATVBAHA.109.200196.CrossRefPubMed

24.

Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, et al. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res. 2010;51(6):1496–503. https://doi.org/10.1194/jlr.M003665.CrossRefPubMedPubMedCentral

25.

Iwata A, Miura S-i, Zhang B, Imaizumi S, Uehara Y, Shiomi M, et al. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis. 2011;218(2):300–7. https://doi.org/10.1016/j.atherosclerosis.2011.05.029.CrossRefPubMed

26.

Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85(4):1234–41. https://doi.org/10.1172/JCI114558. CrossRefPubMedPubMedCentral

27.

Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15(11):1882–8.CrossRefPubMed

28.

Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 2001;103(15):1949–54.CrossRefPubMed

29.

Franceschini G, Sirtori CR, Bosisio E, Gualandri V, Orsini GB, Mogavero AM, et al. Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis. 1985;58(1–3):159–74.CrossRefPubMed

30.

Ibanez B, Giannarelli C, Cimmino G, Santos-Gallego CG, Alique M, Pinero A, et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis. 2012;220(1):72–7. https://doi.org/10.1016/j.atherosclerosis.2011.10.006.CrossRefPubMed

31.

Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292–300. https://doi.org/10.1001/jama.290.17.2292.CrossRefPubMed

32.

Reijers JAA, Kallend DG, Malone KE, Jukema JW, Wijngaard PLJ, Burggraaf J, et al. MDCO-216 does not induce adverse Immunostimulation, in contrast to its predecessor ETC-216. Cardiovasc Drugs Ther. 2017;31(4):381–9. https://doi.org/10.1007/s10557-017-6746-x.CrossRefPubMedPubMedCentral

33.

Tardif J-C. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosisa randomized controlled trial. JAMA. 2007;297(15):1675–82. https://doi.org/10.1001/jama.297.15.jpc70004.CrossRefPubMed

34.

Easton R, Gille A, D'Andrea D, Davis R, Wright Samuel D, Shear C. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Pharmacol. 2013;54(3):301–10. https://doi.org/10.1002/jcph.194.CrossRefPubMed

35.

Michael Gibson C, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, et al. Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I event reducing in ischemic syndromes I). Circulation. 2016;134(24):1918–30. https://doi.org/10.1161/CIRCULATIONAHA.116.025687.CrossRefPubMedPubMedCentral

36.

Tardif J-C, Ballantyne CM, Barter P, Dasseux J-L, Fayad ZA, Guertin M-C, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014;35(46):3277–86. https://doi.org/10.1093/eurheartj/ehu171.CrossRefPubMedPubMedCentral

37.

Kataoka Y, Andrews J, Duong M, Nguyen T, Schwarz N, Fendler J, et al. Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. Cardiovasc Diagn Ther. 2017;7(3):252–63. https://doi.org/10.21037/cdt.2017.02.01.CrossRefPubMedPubMedCentral

38.

Tardy C, Goffinet M, Boubekeur N, Cholez G, Ackermann R, Sy G, et al. HDL and CER-001 inverse-dose dependent inhibition of atherosclerotic plaque formation in apoE−/− mice: evidence of ABCA1 down-regulation. PLoS One. 2015;10(9):e0137584. https://doi.org/10.1371/journal.pone.0137584.CrossRefPubMedPubMedCentral

39.

Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJP, et al. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovasc Diagn Ther. 2017;7(1):45–51. https://doi.org/10.21037/cdt.2017.01.01.CrossRefPubMedPubMedCentral

40.

Kootte RS, Smits LP, van der Valk FM, Dasseux J-L, Keyserling CH, Barbaras R, et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res. 2015;56(3):703–12. https://doi.org/10.1194/jlr.M055665.CrossRefPubMedPubMedCentral

41.

Hovingh GK, Smits LP, Stefanutti C, Soran H, Kwok S, de Graaf J, et al. The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study. Am Heart J. 2015;169(5):736–42.e1. https://doi.org/10.1016/j.ahj.2015.01.008.CrossRefPubMed

42.

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22. https://doi.org/10.1056/NEJMoa0706628. CrossRefPubMed

43.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99. https://doi.org/10.1056/NEJMoa1206797. CrossRefPubMed

44.

Gotto AM, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014;113(1):76–83. https://doi.org/10.1016/j.amjcard.2013.08.041.CrossRefPubMed

45.

Murphy AJ, Dragoljevic D, Tall AR. Cholesterol efflux pathways regulate myelopoiesis: a potential link to altered macrophage function in atherosclerosis. Front Immunol. 2014;5:490. https://doi.org/10.3389/fimmu.2014.00490.CrossRefPubMedPubMedCentral

46.

•• Libby P, Nahrendorf M, Swirski FK. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded "cardiovascular continuum". J Am Coll Cardiol. 2016;67(9):1091–103. https://doi.org/10.1016/j.jacc.2015.12.048. In this article, current views in the pathophysiology of atherosclerosis are discussed. CrossRefPubMedPubMedCentral

47.

• Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science (New York, NY). 2016;351(6278):1166–71. https://doi.org/10.1126/science.aad3517. Recent article suggesting that despite the number of negative trials, the reverse cholesterol transport pathway should not be excluded as a valid therapeutic option. CrossRef

48.

Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 2001;104(20):2447–52.CrossRefPubMed

49.

Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55(21):2399–407. https://doi.org/10.1016/j.jacc.2010.02.026.CrossRefPubMed

Title: HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?
Authors: I. Karalis
J. W. Jukema
Publication date: 01-08-2018
Publisher: Springer US
Published in: Current Cardiology Reports / Issue 8/2018
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-018-1004-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 8/2018

Gender Disparities in Presentation, Management, and Outcomes of Acute Myocardial Infarction

Colchicine in Pericardial Disease: from the Underlying Biology and Clinical Benefits to the Drug-Drug Interactions in Cardiovascular Medicine

Cardiovascular Autonomic Dysfunction in Patients with Cancer

Long-term Management of the Arterial Switch Patient

Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients

Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page